Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids Pharmaceutical Investing
Champignon Brands to Restate Financial Statements and MD&A has Prepared CSE Listing Statement Psychedelics Investing
Thermo Fisher Scientific Acquires Leading Cell Sorting Technology from Propel Labs Medical Device Investing
Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder Pharmaceutical Investing
HempFusion CBD to be the Exclusive Supplier for Clinical Trial at Mount Sinai Medical Hospital, New York Biotech Investing
Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap's Mental Health Technology Psychedelics Investing
Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA® Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis Pharmaceutical Investing
Medtronic Announces Voluntary Recall of Unused Valiant Navion Thoracic Stent Graft System Medical Device Investing
Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
